acetaminophen has been researched along with 2019 Novel Coronavirus Disease in 68 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Insured patients with a history of osteoarthritis or back pain and receiving ibuprofen, other ns-NSAIDs, COX-2i or paracetamol between 1 November, 2019 and 31 January, 2020 (study enrolment window 1) or between 1 February, 2020 and 31 October, 2020 (study enrolment window 2)." | 9.41 | Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study. ( Argyriou, G; Brash, JT; Driessen, S; Prieto-Alhambra, D; Reich, C; Seager, S; Turkmen, C; Varrassi, G; Xie, J, 2023) |
| "Insured patients with a history of osteoarthritis or back pain and receiving ibuprofen, other ns-NSAIDs, COX-2i or paracetamol between 1 November, 2019 and 31 January, 2020 (study enrolment window 1) or between 1 February, 2020 and 31 October, 2020 (study enrolment window 2)." | 5.41 | Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study. ( Argyriou, G; Brash, JT; Driessen, S; Prieto-Alhambra, D; Reich, C; Seager, S; Turkmen, C; Varrassi, G; Xie, J, 2023) |
| "Acetaminophen is widely used to treat mild to moderate pain and to reduce fever." | 4.12 | Formation of Larger Molecular Weight Disinfection Byproducts from Acetaminophen in Chlorine Disinfection. ( Han, J; Li, W; Zhang, X, 2022) |
| " One hundred and seventy-nine (44%) patients had fever, with 32% using paracetamol and 22% using ibuprofen, for symptom-relief." | 3.96 | Ibuprofen use and clinical outcomes in COVID-19 patients. ( Bar-Haim, A; Kozer, E; Rinott, E; Shapira, Y; Youngster, I, 2020) |
| " Globally, the pharmacologic treatment of pain in pediatric patients is limited largely to nonopioid analgesics, and dosing must account for differences in age, weight, metabolism, and risk of adverse effects." | 3.01 | Common Selfcare Indications of Pain Medications in Children. ( Bell, J; Kachroo, P; Mossali, VM; Siddiqui, K; Zempsky, W, 2023) |
| " There were no serious adverse events related to ChAdOx1 nCoV-19." | 2.94 | Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. ( Aley, PK; Angus, B; Becker, S; Belij-Rammerstorfer, S; Bellamy, D; Bibi, S; Bittaye, M; Clutterbuck, EA; Dold, C; Douglas, AD; Ewer, KJ; Faust, SN; Finn, A; Flaxman, AL; Folegatti, PM; Gilbert, SC; Green, C; Hallis, B; Heath, P; Hill, AVS; Jenkin, D; Lambe, T; Lazarus, R; Makinson, R; Minassian, AM; Pollard, AJ; Pollock, KM; Ramasamy, M; Robinson, H; Snape, M; Tarrant, R; Voysey, M, 2020) |
| "The developed methods are successfully applied for concurrent quantification of the studied components in the marketed dosage form without interference from matrix excipients." | 2.82 | Novel Spectrophotometric Approaches for the Simultaneous Quantification of Ternary Common Cold Mixture Containing Paracetamol with a Challenging Formulation Ratio: Greenness Profile Evaluation. ( Fayez, YM; Monir, HH; Mostafa, NM; Rostom, Y; Soliman, RM, 2022) |
| "Fomepizole is a promising new treatment for preventing liver injury following paracetamol (acetaminophen) overdose." | 1.91 | Fomepizole should not be used more liberally in paracetamol overdose. ( Dear, JW, 2023) |
| "Acetaminophen plays a key role in first-line Covid-19 cure as a supportive therapy of fever and pain." | 1.91 | Sensitive electrochemical assay of acetaminophen based on 3D-hierarchical mesoporous carbon nanosheets. ( Caddeo, F; Chen, J; Huang, Q; Huang, S; Jin, M; Liu, X; Liu, Z; Shui, L; Xie, P; Yan, Y, 2023) |
| " The advantages of the proposed method qualify it for routine analysis of the studied drugs either in single or co-formulated dosage form in quality control labs." | 1.91 | A quality-by-design eco-friendly UV-HPLC method for the determination of four drugs used to treat symptoms of common cold and COVID-19. ( Abdallah, NA; El-Brashy, AM; Fathy, ME; Ibrahim, FA; Tolba, MM, 2023) |
| "During the outbreak of COVID19 measures taken to contain the spread of the virus have influenced the mental well-being of adults and adolescents." | 1.91 | Early treatment with N-acetylcysteine reduces hepatotoxicity in acute acetaminophen poisoning. ( Capossela, L; Chiaretti, A; Curatola, A; Ferretti, S; Gatto, A; Graglia, B; Pansini, V, 2023) |
| "Acetaminophen (APAP) is a worldwide antipyretic as well as an analgesic medication." | 1.72 | Diacerein ameliorates acetaminophen hepatotoxicity in rats via inhibiting HMGB1/TLR4/NF-κB and upregulating PPAR-γ signal. ( Harahsheh, E; Hussein, S; Mohamed Kamel, GA, 2022) |
| "Headache is the most common COVID-19-related neurological symptom." | 1.72 | Patterns of COVID-19-related headache: A cross-sectional study. ( Celikbilek, A; Hizmali, L; Kocak, Y; Sahin, BE, 2022) |
| "Acetaminophen was the most common agent reported." | 1.72 | The Toxicology Investigators Consortium Case Registry-the 2021 Annual Report. ( Aldy, K; Brent, J; Campleman, SL; Farrugia, LA; Kang, AM; Karshenas, DL; Li, S; Love, JS; Nguyen, H; Spyres, MB; Wax, PM, 2022) |
| " APAP is safe at therapeutic levels, however, an overdose can cause severe liver injury." | 1.62 | Potential benefits of using hydrogen sulfide, vitamin E and necrostatin-1 to counteract acetaminophen‑induced hepatotoxicity in rats. ( Abdel-Hakeem, EA; El-Tahawy, NF; Elbassuoni, EA; Saad, AH; Saleh, NEH, 2021) |
| "The study aimed at exploring the adverse events following immunization (AEFI) and their incidences among health workers in three different districts of central and western Nepal following the first dose of Covishield vaccine,." | 1.62 | Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study. ( Paudel, B; Pyakurel, P; Regmi, A; Subedi, P; Yadav, GK, 2021) |
| "Acetaminophen was highest used drug for analgesic purposes without prescriptions (n=101 participants, 57%)." | 1.62 | Self-medication practice with analgesics (NSAIDs and acetaminophen), and antibiotics among nursing undergraduates in University College Farasan Campus, Jazan University, KSA. ( Faqihi, AHMA; Sayed, SF, 2021) |
| "Pain is a common but often ignored symptom in COVID-19 patients." | 1.62 | COVID-19'da İhmal Edilen Semptom: Ağrı. ( Sir, E, 2021) |
| "The pandemic of coronavirus disease 2019 (COVID-19) has emerged as a relevant threat for humans worldwide." | 1.56 | Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19. ( Angeli, P; Benfaremo, D; Cattelan, A; Cerruti, L; Dalbeni, A; Framba, V; Gambino, CG; Luchetti, MM; Mantovani, A; Martini, A; Mattioli, M; Piano, S; Serra, R; Vettor, R; Vettore, E, 2020) |
| " Treatment of common co-morbidities often require chronic use of multiple medications, which may result in an additive increase in the expression of ACE2 and TMPRSS2." | 1.56 | Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. ( Abusnana, S; Al Heialy, S; Alghamdi, M; Halwani, R; Hamid, Q; Kashour, T; Mdkhana, B; Ratemi, E; Saheb Sharif-Askari, F; Saheb Sharif-Askari, N, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 68 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Saleh, NEH | 1 |
| Saad, AH | 1 |
| Elbassuoni, EA | 1 |
| El-Tahawy, NF | 1 |
| Abdel-Hakeem, EA | 1 |
| Saifuddin, A | 1 |
| Koesnoe, S | 1 |
| Kurniati, N | 1 |
| Sirait, S | 1 |
| Arisanty, R | 1 |
| Yunihastuti, E | 1 |
| Kokawa, T | 1 |
| Yamamoto, H | 1 |
| Itoh, M | 1 |
| Shimane, A | 1 |
| Kawai, H | 1 |
| Takaya, T | 1 |
| Subedi, P | 1 |
| Yadav, GK | 1 |
| Paudel, B | 1 |
| Regmi, A | 1 |
| Pyakurel, P | 1 |
| Mahmood Alam, J | 1 |
| Asghar, SS | 1 |
| Ali, H | 1 |
| Mahmood, SR | 1 |
| Ansari, MA | 1 |
| de Bruin, N | 1 |
| Schneider, AK | 1 |
| Reus, P | 1 |
| Talmon, S | 1 |
| Ciesek, S | 1 |
| Bojkova, D | 1 |
| Cinatl, J | 1 |
| Lodhi, I | 1 |
| Charlesworth, B | 1 |
| Sinclair, S | 1 |
| Pennick, G | 1 |
| Laughey, WF | 1 |
| Gribbon, P | 1 |
| Kannt, A | 1 |
| Schiffmann, S | 1 |
| Mohamed Kamel, GA | 1 |
| Harahsheh, E | 1 |
| Hussein, S | 1 |
| Ahmed, DA | 1 |
| Lotfy, HM | 1 |
| Finsterer, J | 1 |
| Sahin, BE | 1 |
| Celikbilek, A | 1 |
| Kocak, Y | 1 |
| Hizmali, L | 1 |
| Krbečková, V | 1 |
| Šimonová, Z | 1 |
| Langer, P | 1 |
| Peikertová, P | 1 |
| Kutláková, KM | 1 |
| Thomasová, B | 1 |
| Plachá, D | 1 |
| Soliman, RM | 1 |
| Mostafa, NM | 1 |
| Fayez, YM | 1 |
| Monir, HH | 1 |
| Rostom, Y | 1 |
| Hayden, KR | 1 |
| Jones, M | 1 |
| Elkin, KR | 1 |
| Shreve, MJ | 1 |
| Clees, WI | 1 |
| Clark, S | 1 |
| Mashtare, ML | 1 |
| Veith, TL | 1 |
| Elliott, HA | 1 |
| Watson, JE | 1 |
| Silverman, J | 1 |
| Richard, TL | 1 |
| Read, AF | 1 |
| Preisendanz, HE | 1 |
| Abdool-Ghany, AA | 1 |
| Sahwell, PJ | 1 |
| Klaus, J | 1 |
| Gidley, ML | 1 |
| Sinigalliano, CD | 1 |
| Solo-Gabriele, HM | 1 |
| Masui, R | 1 |
| Komiya, K | 1 |
| Tanaka, A | 1 |
| Matsumoto, H | 1 |
| Yoshikawa, H | 1 |
| Ichihara, S | 1 |
| Yamanaka, M | 1 |
| Yokoyama, A | 1 |
| Hiramatsu, K | 1 |
| Kadota, JI | 1 |
| Love, JS | 1 |
| Karshenas, DL | 1 |
| Spyres, MB | 1 |
| Farrugia, LA | 1 |
| Kang, AM | 1 |
| Nguyen, H | 1 |
| Campleman, SL | 1 |
| Li, S | 1 |
| Wax, PM | 1 |
| Brent, J | 1 |
| Aldy, K | 1 |
| Georgin, J | 1 |
| Franco, DSP | 1 |
| Netto, MS | 1 |
| Manzar, MS | 1 |
| Zubair, M | 1 |
| Meili, L | 1 |
| Piccilli, DGA | 1 |
| Silva, LFO | 1 |
| Moss, RE | 1 |
| Hertzberg, EH | 1 |
| Person, H | 1 |
| Stoffels, G | 1 |
| Zackai, S | 1 |
| Bucuvalas, J | 1 |
| Gillen, JK | 1 |
| McClatchy, J | 1 |
| Yap, T | 1 |
| Nirenberg, A | 1 |
| Scardamaglia, L | 1 |
| Chirumbolo, S | 3 |
| Li, W | 3 |
| Zhang, X | 3 |
| Han, J | 3 |
| Oluyase, AO | 3 |
| Bajwah, S | 3 |
| Sleeman, KE | 3 |
| Walshe, C | 3 |
| Preston, N | 3 |
| Hocaoglu, M | 3 |
| Bradshaw, A | 3 |
| Chambers, RL | 3 |
| Murtagh, FEM | 3 |
| Dunleavy, L | 3 |
| Maddocks, M | 3 |
| Fraser, LK | 3 |
| Higginson, IJ | 3 |
| Dear, JW | 2 |
| Yan, Y | 1 |
| Liu, Z | 1 |
| Xie, P | 1 |
| Huang, S | 1 |
| Chen, J | 1 |
| Caddeo, F | 1 |
| Liu, X | 2 |
| Huang, Q | 1 |
| Jin, M | 1 |
| Shui, L | 1 |
| Baldia, PH | 1 |
| Wernly, B | 1 |
| Flaatten, H | 1 |
| Fjølner, J | 1 |
| Artigas, A | 1 |
| Pinto, BB | 1 |
| Schefold, JC | 1 |
| Kelm, M | 1 |
| Beil, M | 1 |
| Bruno, RR | 1 |
| Binnebößel, S | 1 |
| Wolff, G | 1 |
| Erkens, R | 1 |
| Sigal, S | 1 |
| van Heerden, PV | 1 |
| Szczeklik, W | 1 |
| Elhadi, M | 1 |
| Joannidis, M | 1 |
| Oeyen, S | 1 |
| Marsh, B | 1 |
| Andersen, FH | 1 |
| Moreno, R | 1 |
| Leaver, S | 1 |
| De Lange, DW | 2 |
| Guidet, B | 1 |
| Jung, C | 1 |
| Valdenassi, L | 1 |
| Simonetti, V | 2 |
| Pandolfi, S | 2 |
| Xie, J | 1 |
| Brash, JT | 1 |
| Turkmen, C | 1 |
| Driessen, S | 1 |
| Varrassi, G | 1 |
| Argyriou, G | 1 |
| Seager, S | 1 |
| Reich, C | 1 |
| Prieto-Alhambra, D | 1 |
| Abdallah, NA | 1 |
| Fathy, ME | 1 |
| Tolba, MM | 1 |
| El-Brashy, AM | 1 |
| Ibrahim, FA | 1 |
| Domínguez-García, P | 1 |
| Rodríguez, RR | 1 |
| Barata, C | 1 |
| Gómez-Canela, C | 1 |
| Karami, S | 1 |
| Asonye, C | 1 |
| Pinnow, E | 1 |
| Pratt, V | 1 |
| McCulley, L | 1 |
| Dwumfour, N | 1 |
| Zhou, EH | 1 |
| Kim, JW | 1 |
| Yoon, S | 1 |
| Lee, J | 1 |
| Lee, S | 1 |
| Zempsky, W | 1 |
| Bell, J | 1 |
| Mossali, VM | 1 |
| Kachroo, P | 1 |
| Siddiqui, K | 1 |
| Lapi, F | 1 |
| Marconi, E | 1 |
| Grattagliano, I | 1 |
| Rossi, A | 1 |
| Fornasari, D | 1 |
| Magni, A | 1 |
| Aprile, PL | 1 |
| Cricelli, C | 1 |
| Koppen, A | 1 |
| Thoonen, IMJ | 1 |
| Hunault, CC | 1 |
| van Velzen, AG | 1 |
| Rietjens, SJ | 1 |
| Mekonnen, Z | 1 |
| Melaku, T | 1 |
| Tucho, GT | 1 |
| Mecha, M | 1 |
| Årdal, C | 1 |
| Jahre, M | 1 |
| Ferretti, S | 1 |
| Curatola, A | 1 |
| Chiaretti, A | 1 |
| Graglia, B | 1 |
| Gatto, A | 1 |
| Capossela, L | 1 |
| Pansini, V | 1 |
| Apata, J | 1 |
| Pennap, DD | 1 |
| Mosholder, AD | 1 |
| Moussa, AA | 1 |
| Omar, FD | 1 |
| Fiidow, OA | 1 |
| Ali, FH | 1 |
| Babatunde, SM | 1 |
| Xu, X | 1 |
| Li, J | 1 |
| Deng, X | 1 |
| Dai, T | 1 |
| Ji, Q | 1 |
| Xiong, D | 1 |
| Xie, H | 1 |
| Sodhi, M | 1 |
| Etminan, M | 1 |
| Goodnough, R | 1 |
| Canseco, K | 1 |
| Rodríguez-Morales, AJ | 1 |
| Cardona-Ospina, JA | 1 |
| Murillo-Muñoz, MM | 1 |
| Gasbarrini, G | 1 |
| Elgamasy, S | 1 |
| Kamel, MG | 1 |
| Ghozy, S | 1 |
| Khalil, A | 1 |
| Morra, ME | 1 |
| Islam, SMS | 1 |
| Della-Torre, E | 1 |
| Della-Torre, F | 1 |
| Kusanovic, M | 1 |
| Scotti, R | 1 |
| Ramirez, GA | 1 |
| Dagna, L | 1 |
| Tresoldi, M | 1 |
| Piano, S | 1 |
| Dalbeni, A | 1 |
| Vettore, E | 1 |
| Benfaremo, D | 1 |
| Mattioli, M | 1 |
| Gambino, CG | 1 |
| Framba, V | 1 |
| Cerruti, L | 1 |
| Mantovani, A | 1 |
| Martini, A | 1 |
| Luchetti, MM | 1 |
| Serra, R | 1 |
| Cattelan, A | 1 |
| Vettor, R | 1 |
| Angeli, P | 1 |
| Rinott, E | 1 |
| Kozer, E | 1 |
| Shapira, Y | 1 |
| Bar-Haim, A | 1 |
| Youngster, I | 1 |
| Crighton, AJ | 1 |
| McCann, CT | 1 |
| Todd, EJ | 1 |
| Brown, AJ | 1 |
| Folegatti, PM | 1 |
| Ewer, KJ | 1 |
| Aley, PK | 1 |
| Angus, B | 1 |
| Becker, S | 1 |
| Belij-Rammerstorfer, S | 1 |
| Bellamy, D | 1 |
| Bibi, S | 1 |
| Bittaye, M | 1 |
| Clutterbuck, EA | 1 |
| Dold, C | 1 |
| Faust, SN | 1 |
| Finn, A | 2 |
| Flaxman, AL | 1 |
| Hallis, B | 1 |
| Heath, P | 1 |
| Jenkin, D | 1 |
| Lazarus, R | 1 |
| Makinson, R | 1 |
| Minassian, AM | 1 |
| Pollock, KM | 1 |
| Ramasamy, M | 1 |
| Robinson, H | 1 |
| Snape, M | 1 |
| Tarrant, R | 1 |
| Voysey, M | 1 |
| Green, C | 1 |
| Douglas, AD | 1 |
| Hill, AVS | 1 |
| Lambe, T | 1 |
| Gilbert, SC | 1 |
| Pollard, AJ | 1 |
| Ruano, FJ | 1 |
| Somoza Álvarez, ML | 1 |
| Haroun-Díaz, E | 1 |
| Vázquez de la Torre, M | 1 |
| López González, P | 1 |
| Prieto-Moreno, A | 1 |
| Torres Rojas, I | 1 |
| Cervera García, MD | 1 |
| Pérez Alzate, D | 1 |
| Blanca-López, N | 1 |
| Canto Díez, G | 1 |
| Aksan, F | 1 |
| Nelson, EA | 1 |
| Swedish, KA | 1 |
| Saheb Sharif-Askari, N | 1 |
| Saheb Sharif-Askari, F | 1 |
| Mdkhana, B | 1 |
| Al Heialy, S | 1 |
| Ratemi, E | 1 |
| Alghamdi, M | 1 |
| Abusnana, S | 1 |
| Kashour, T | 1 |
| Hamid, Q | 1 |
| Halwani, R | 1 |
| Abd-Elsalam, S | 1 |
| Esmail, ES | 1 |
| Khalaf, M | 1 |
| Abdo, EF | 1 |
| Medhat, MA | 1 |
| Abd El Ghafar, MS | 1 |
| Ahmed, OA | 1 |
| Soliman, S | 1 |
| Serangawy, GN | 1 |
| Alboraie, M | 1 |
| Rouphael, C | 1 |
| D'Amico, G | 1 |
| Ricci, K | 1 |
| Cywinski, J | 1 |
| Miranda, C | 1 |
| Koval, C | 1 |
| Duggal, A | 1 |
| Quintini, C | 1 |
| Menon, KVN | 1 |
| Miller, C | 1 |
| Modaresi Esfeh, J | 1 |
| Silveira, D | 1 |
| Cabbab, ILN | 1 |
| Manalo, RVM | 1 |
| Faqihi, AHMA | 1 |
| Sayed, SF | 1 |
| Raveh, Y | 1 |
| Simkins, J | 1 |
| Nicolau-Raducu, R | 1 |
| Chandan, JS | 1 |
| Zemedikun, DT | 1 |
| Thayakaran, R | 1 |
| Byne, N | 1 |
| Dhalla, S | 1 |
| Acosta-Mena, D | 1 |
| Gokhale, KM | 1 |
| Thomas, T | 1 |
| Sainsbury, C | 1 |
| Subramanian, A | 1 |
| Cooper, J | 1 |
| Anand, A | 1 |
| Okoth, KO | 1 |
| Wang, J | 1 |
| Adderley, NJ | 1 |
| Taverner, T | 1 |
| Denniston, AK | 1 |
| Lord, J | 1 |
| Thomas, GN | 1 |
| Buckley, CD | 1 |
| Raza, K | 1 |
| Bhala, N | 1 |
| Nirantharakumar, K | 1 |
| Haroon, S | 1 |
| Zarubin, A | 1 |
| Stepanov, V | 1 |
| Markov, A | 1 |
| Kolesnikov, N | 1 |
| Marusin, A | 1 |
| Khitrinskaya, I | 1 |
| Swarovskaya, M | 1 |
| Litvinov, S | 1 |
| Ekomasova, N | 1 |
| Dzhaubermezov, M | 1 |
| Maksimova, N | 1 |
| Sukhomyasova, A | 1 |
| Shtygasheva, O | 1 |
| Khusnutdinova, E | 1 |
| Radzhabov, M | 1 |
| Kharkov, V | 1 |
| Veraldi, S | 1 |
| Romagnuolo, M | 1 |
| Benzecry, V | 1 |
| Ibrahim, H | 1 |
| Hamdy, AM | 1 |
| Merey, HA | 1 |
| Saad, AS | 1 |
| Park, J | 1 |
| Lee, SH | 1 |
| You, SC | 1 |
| Kim, J | 1 |
| Yang, K | 1 |
| Ortiz-Prado, E | 1 |
| Fernandez-Naranjo, R | 1 |
| Torres-Berru, Y | 1 |
| Lowe, R | 1 |
| Torres, I | 1 |
| Southren, DL | 1 |
| Nardone, AD | 1 |
| Haastrup, AA | 1 |
| Roberts, RJ | 1 |
| Chang, MG | 1 |
| Bittner, EA | 1 |
| Ricevuti, G | 1 |
| Sir, E | 1 |
| King, H | 1 |
| Deshpande, S | 1 |
| Woodbridge, T | 1 |
| Hilliard, T | 1 |
| Standing, J | 1 |
| Lewis, M | 1 |
| Ward, L | 1 |
| Roderick, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers[NCT04324606] | Phase 1/Phase 2 | 1,090 participants (Actual) | Interventional | 2020-04-23 | Active, not recruiting | ||
| Antibody Response After COVID-19 Vaccination in Chronic Kidney Disease and Kidney Transplant Patients[NCT05057936] | 140 participants (Actual) | Observational | 2021-06-01 | Completed | |||
| A Prospective Study Comparing the Antibody Response of Subjects With Chronic Liver Disease to mRNA, Inactivated Virus and Adenovirus Vector COVID-19 Vaccines[NCT04775069] | Phase 4 | 232 participants (Actual) | Interventional | 2021-05-21 | Completed | ||
| Immunogenicity of the ChAdox1 n CoV-19 Vaccine Against SARS-CoV-2 With 12-dose Vials: an Interim Analysis[NCT04961385] | 60 participants (Actual) | Observational | 2021-04-01 | Completed | |||
| Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death[NCT04914832] | Phase 4 | 75,012 participants (Actual) | Interventional | 2021-08-30 | Completed | ||
| Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2[NCT04894409] | 231 participants (Actual) | Interventional | 2020-04-24 | Completed | |||
| Serology Testing (Antibody Levels) With Time Following SARS-CoV-2 (Covid-19) Vaccinations in Residents of Nursing, Extended Care, and Over-55 Communities[NCT04944095] | 10,000 participants (Anticipated) | Observational | 2021-08-10 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for acetaminophen and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Novel Spectrophotometric Approaches for the Simultaneous Quantification of Ternary Common Cold Mixture Containing Paracetamol with a Challenging Formulation Ratio: Greenness Profile Evaluation.
Topics: Acetaminophen; Common Cold; Cough; COVID-19; Humans; Pseudoephedrine; Spectrophotometry | 2022 |
Fixed drug eruptions - the common and novel culprits since 2000.
Topics: Acetaminophen; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; COVID-19; COVID-19 Va | 2022 |
Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Back Pain; Cohort Studies; COVID-19; COVID-1 | 2023 |
Common Selfcare Indications of Pain Medications in Children.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; COVID-19; Fever; Humans; Ibuprofen; Pain | 2023 |
Environmental Risk Factors, Protective Factors, and Biomarkers for Allergic Rhinitis: A Systematic Umbrella Review of the Evidence.
Topics: Acetaminophen; Biomarkers; Child; COVID-19; Humans; Protective Factors; Rhinitis, Allergic; Risk Fac | 2023 |
Safe use of paracetamol and high-dose NSAID analgesia in dentistry during the COVID-19 pandemic.
Topics: Acetaminophen; Analgesia; Anti-Inflammatory Agents, Non-Steroidal; Betacoronavirus; Coronavirus Infe | 2020 |
Anti-inflammatory drugs and the renin-angiotensin-aldosterone system: Current knowledge and potential effects on early SARS-CoV-2 infection.
Topics: Acetaminophen; Angiotensin-Converting Enzyme 2; Animals; Anti-Inflammatory Agents; COVID-19; COVID-1 | 2021 |
2 trials available for acetaminophen and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Topics: Acetaminophen; Adenoviruses, Simian; Adult; Analgesics, Non-Narcotic; Antibodies, Neutralizing; Anti | 2020 |
RETRACTED: Hydroxychloroquine in the Treatment of COVID-19: A Multicenter Randomized Controlled Study.
Topics: Acetaminophen; Adult; Antiviral Agents; Betacoronavirus; Cephalosporins; Coronavirus Infections; COV | 2020 |
59 other studies available for acetaminophen and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Potential benefits of using hydrogen sulfide, vitamin E and necrostatin-1 to counteract acetaminophen‑induced hepatotoxicity in rats.
Topics: Acetaminophen; Alanine Transaminase; Animals; Aspartate Aminotransferases; Chemical and Drug Induced | 2021 |
COVID Arm After Moderna Booster in Healthcare Worker: A Case Report.
Topics: 2019-nCoV Vaccine mRNA-1273; Acetaminophen; Analgesics, Non-Narcotic; Biopsy; COVID-19; COVID-19 Vac | 2021 |
Fever-Related Ventricular Fibrillation - Potential Adverse Effect of SARS-CoV-2 Vaccination in Patients With Brugada Syndrome.
Topics: Acetaminophen; Adult; Anti-Arrhythmia Agents; Antipyretics; Arrhythmias, Cardiac; Brugada Syndrome; | 2022 |
Adverse events following the first dose of Covishield (ChAdOx1 nCoV-19) vaccination among health workers in selected districts of central and western Nepal: A cross-sectional study.
Topics: Acetaminophen; Adult; Aged; ChAdOx1 nCoV-19; Comorbidity; COVID-19; Cross-Sectional Studies; Female; | 2021 |
REPORT- Varying pattern of blood gases, ferritin, procalcitonin, C-Reactive protein, interleukin 6 and lactate dehydrogenase in Covid-19 patients suffering from diverse Co-Morbid, suspected cytokine storm and periodic effects of antiviral and steroidal tr
Topics: Acetaminophen; Antipyretics; Antiviral Agents; Biomarkers; Blood Gas Analysis; C-Reactive Protein; C | 2021 |
Ibuprofen, Flurbiprofen, Etoricoxib or Paracetamol Do Not Influence ACE2 Expression and Activity In Vitro or in Mice and Do Not Exacerbate In-Vitro SARS-CoV-2 Infection.
Topics: Acetaminophen; Angiotensin-Converting Enzyme 2; Animals; Anti-Inflammatory Agents, Non-Steroidal; Ca | 2022 |
Diacerein ameliorates acetaminophen hepatotoxicity in rats via inhibiting HMGB1/TLR4/NF-κB and upregulating PPAR-γ signal.
Topics: Acetaminophen; Animals; Anthraquinones; Antioxidants; Chemical and Drug Induced Liver Injury; COVID- | 2022 |
Sticking - pulling strategy for assessment of combined medicine for management of tough symptoms in COVID-19 Pandemic using different windows of spectrophotometric Platform-Counterfeit products' detection.
Topics: Acetaminophen; Calibration; COVID-19; COVID-19 Drug Treatment; Humans; Pandemics; Spectrophotometry | 2022 |
Letter to the Editor: Propacetamol-Induced Rhabdomyolysis or COVID-Vaccine-Related Inflammatory Myopathy?
Topics: Acetaminophen; BNT162 Vaccine; COVID-19; COVID-19 Vaccines; Humans; Myositis; Rhabdomyolysis; Vaccin | 2022 |
Patterns of COVID-19-related headache: A cross-sectional study.
Topics: Acetaminophen; COVID-19; Cross-Sectional Studies; Female; Headache; Humans; SARS-CoV-2 | 2022 |
Effective and reproducible biosynthesis of nanogold-composite catalyst for paracetamol oxidation.
Topics: Acetaminophen; COVID-19; Gold; Humans; Metal Nanoparticles; Pandemics | 2022 |
Impacts of the COVID-19 pandemic on pharmaceuticals in wastewater treated for beneficial reuse: Two case studies in central Pennsylvania.
Topics: Acetaminophen; Ampicillin; Animals; Anti-Bacterial Agents; COVID-19; Dexamethasone; Doxycycline; Env | 2022 |
Fecal indicator bacteria levels at a marine beach before, during, and after the COVID-19 shutdown period and associations with decomposing seaweed and human presence.
Topics: Acetaminophen; Animals; Bacteria; Bathing Beaches; Caffeine; COVID-19; Dogs; Enterococcus; Environme | 2022 |
Intravenous acetaminophen-induced non-anaphylactic shock in an older patient with COVID-19.
Topics: Acetaminophen; Administration, Intravenous; COVID-19; Humans; Hypotension | 2022 |
The Toxicology Investigators Consortium Case Registry-the 2021 Annual Report.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Antidotes; COVID-19; Drug Overdose; Fem | 2022 |
Adsorption of the First-Line Covid Treatment Analgesic onto Activated Carbon from Residual Pods of Erythrina Speciosa.
Topics: Acetaminophen; Adsorption; Analgesics; Charcoal; COVID-19; Erythrina; Hydrogen-Ion Concentration; Ki | 2023 |
Increase in Rate of Hospitalizations for Pediatric Intentional Acetaminophen Ingestion at a Single Center During the COVID-19 Pandemic.
Topics: Acetaminophen; Adolescent; Child; COVID-19; Eating; Female; Hospitalization; Humans; Pandemics; Retr | 2023 |
The widest use of paracetamol in home therapy might have actually increased the occurrence of severe forms of COVID-19 in Italy, affecting hospitalization and death rates.
Topics: Acetaminophen; COVID-19; Hospitalization; Humans; Italy; SARS-CoV-2 | 2023 |
Formation of Larger Molecular Weight Disinfection Byproducts from Acetaminophen in Chlorine Disinfection.
Topics: Acetaminophen; Chlorine; COVID-19; Disinfectants; Disinfection; Drinking Water; Halogenation; Humans | 2022 |
Formation of Larger Molecular Weight Disinfection Byproducts from Acetaminophen in Chlorine Disinfection.
Topics: Acetaminophen; Chlorine; COVID-19; Disinfectants; Disinfection; Drinking Water; Halogenation; Humans | 2022 |
Formation of Larger Molecular Weight Disinfection Byproducts from Acetaminophen in Chlorine Disinfection.
Topics: Acetaminophen; Chlorine; COVID-19; Disinfectants; Disinfection; Drinking Water; Halogenation; Humans | 2022 |
Formation of Larger Molecular Weight Disinfection Byproducts from Acetaminophen in Chlorine Disinfection.
Topics: Acetaminophen; Chlorine; COVID-19; Disinfectants; Disinfection; Drinking Water; Halogenation; Humans | 2022 |
Formation of Larger Molecular Weight Disinfection Byproducts from Acetaminophen in Chlorine Disinfection.
Topics: Acetaminophen; Chlorine; COVID-19; Disinfectants; Disinfection; Drinking Water; Halogenation; Humans | 2022 |
Formation of Larger Molecular Weight Disinfection Byproducts from Acetaminophen in Chlorine Disinfection.
Topics: Acetaminophen; Chlorine; COVID-19; Disinfectants; Disinfection; Drinking Water; Halogenation; Humans | 2022 |
Formation of Larger Molecular Weight Disinfection Byproducts from Acetaminophen in Chlorine Disinfection.
Topics: Acetaminophen; Chlorine; COVID-19; Disinfectants; Disinfection; Drinking Water; Halogenation; Humans | 2022 |
Formation of Larger Molecular Weight Disinfection Byproducts from Acetaminophen in Chlorine Disinfection.
Topics: Acetaminophen; Chlorine; COVID-19; Disinfectants; Disinfection; Drinking Water; Halogenation; Humans | 2022 |
Formation of Larger Molecular Weight Disinfection Byproducts from Acetaminophen in Chlorine Disinfection.
Topics: Acetaminophen; Chlorine; COVID-19; Disinfectants; Disinfection; Drinking Water; Halogenation; Humans | 2022 |
Symptom management in people dying with COVID-19: multinational observational study.
Topics: Acetaminophen; Benzodiazepines; Cough; COVID-19; Humans; Palliative Care | 2022 |
Symptom management in people dying with COVID-19: multinational observational study.
Topics: Acetaminophen; Benzodiazepines; Cough; COVID-19; Humans; Palliative Care | 2022 |
Symptom management in people dying with COVID-19: multinational observational study.
Topics: Acetaminophen; Benzodiazepines; Cough; COVID-19; Humans; Palliative Care | 2022 |
Symptom management in people dying with COVID-19: multinational observational study.
Topics: Acetaminophen; Benzodiazepines; Cough; COVID-19; Humans; Palliative Care | 2022 |
Symptom management in people dying with COVID-19: multinational observational study.
Topics: Acetaminophen; Benzodiazepines; Cough; COVID-19; Humans; Palliative Care | 2022 |
Symptom management in people dying with COVID-19: multinational observational study.
Topics: Acetaminophen; Benzodiazepines; Cough; COVID-19; Humans; Palliative Care | 2022 |
Symptom management in people dying with COVID-19: multinational observational study.
Topics: Acetaminophen; Benzodiazepines; Cough; COVID-19; Humans; Palliative Care | 2022 |
Symptom management in people dying with COVID-19: multinational observational study.
Topics: Acetaminophen; Benzodiazepines; Cough; COVID-19; Humans; Palliative Care | 2022 |
Symptom management in people dying with COVID-19: multinational observational study.
Topics: Acetaminophen; Benzodiazepines; Cough; COVID-19; Humans; Palliative Care | 2022 |
Fomepizole should not be used more liberally in paracetamol overdose.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; COV | 2023 |
Fomepizole should not be used more liberally in paracetamol overdose.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; COV | 2023 |
Fomepizole should not be used more liberally in paracetamol overdose.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; COV | 2023 |
Fomepizole should not be used more liberally in paracetamol overdose.
Topics: Acetaminophen; Acetylcysteine; Analgesics, Non-Narcotic; Chemical and Drug Induced Liver Injury; COV | 2023 |
Sensitive electrochemical assay of acetaminophen based on 3D-hierarchical mesoporous carbon nanosheets.
Topics: Acetaminophen; Animals; Carbon; COVID-19; Electrochemical Techniques; Electrodes; Pharmaceutical Pre | 2023 |
The association of prior paracetamol intake with outcome of very old intensive care patients with COVID-19: results from an international prospective multicentre trial.
Topics: Acetaminophen; COVID-19; Critical Care; Critical Illness; Humans; Pandemics; Prospective Studies | 2022 |
Comments on "To clarify the safety profile of paracetamol for home-care patients with COVID-19: a real-world cohort study, with nested case-control analysis, in primary care".
Topics: Acetaminophen; Case-Control Studies; Cohort Studies; COVID-19; Humans; Primary Health Care | 2023 |
A quality-by-design eco-friendly UV-HPLC method for the determination of four drugs used to treat symptoms of common cold and COVID-19.
Topics: Acetaminophen; Ambroxol; Chromatography, High Pressure Liquid; Common Cold; COVID-19; Humans; Phenyl | 2023 |
Presence and toxicity of drugs used to treat SARS-CoV-2 in Llobregat River, Catalonia, Spain.
Topics: Acetaminophen; Chromatography, Liquid; COVID-19; COVID-19 Drug Treatment; Dexamethasone; Environment | 2023 |
Trends in pediatric nonprescription analgesic/antipyretic exposures during the COVID-19 pandemic.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Antipyretics; Aspirin; Child; Child, Preschool; | 2023 |
Serious Clinical Outcomes of COVID-19 Related to Acetaminophen or NSAIDs from a Nationwide Population-Based Cohort Study.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; COVID-19; Humans; SARS-CoV-2 | 2023 |
"To clarify the safety profile of paracetamol for home-care patients with COVID-19: a real-world cohort study, with nested case-control analysis, in primary care"-Reply.
Topics: Acetaminophen; Case-Control Studies; Cohort Studies; COVID-19; Humans; Primary Health Care | 2023 |
Significant Increase in Deliberate Self-Poisonings Among Adolescents During the Second Year of the COVID-19 Pandemic.
Topics: Acetaminophen; Adolescent; Communicable Disease Control; COVID-19; Female; Humans; Pandemics; Retros | 2023 |
The knock-on effects of COVID-19 pandemic on the supply and availability of generic medicines in Ethiopia: mixed methods study.
Topics: Acetaminophen; COVID-19; Drugs, Essential; Drugs, Generic; Ethiopia; Health Services Accessibility; | 2023 |
Early treatment with N-acetylcysteine reduces hepatotoxicity in acute acetaminophen poisoning.
Topics: Acetaminophen; Acetylcysteine; Adolescent; Adult; Chemical and Drug Induced Liver Injury; Child; COV | 2023 |
The use of analgesics for intentional self-poisoning: Trends in U.S. poison center data.
Topics: Acetaminophen; Adolescent; Adult; Analgesics; Aspirin; Child; COVID-19; Female; Humans; Ibuprofen; M | 2023 |
Self-medication practices against COVID-19 infection and awareness among residents of Mogadishu, Somalia: A cross-sectional analysis.
Topics: Acetaminophen; Anti-Bacterial Agents; COVID-19; Cross-Sectional Studies; Humans; Somalia | 2023 |
Safety of Ibuprofen in Patients With COVID-19: Causal or Confounded?
Topics: Acetaminophen; Antipyretics; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Ibuprofen; P | 2020 |
Truncated IV acetylcysteine treatment duration has potential to safely preserve resources during the COVID-19 pandemic.
Topics: Acetaminophen; Acetylcysteine; COVID-19; Duration of Therapy; Humans; Pandemics; SARS-CoV-2 | 2021 |
Gastroenterologists, Hepatologists, COVID-19 and the Use of Acetaminophen.
Topics: Acetaminophen; Betacoronavirus; Coronavirus Infections; COVID-19; Gastroenterologists; Humans; Pande | 2020 |
COVID-19: thoughts at sunrise.
Topics: Acetaminophen; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Pandemics; Pneumonia, Vira | 2020 |
First case of focal epilepsy associated with SARS-coronavirus-2.
Topics: Acetaminophen; Acetylcysteine; Aged; Ambroxol; Anticonvulsants; Cough; COVID-19; COVID-19 Drug Treat | 2020 |
Treating COVID-19 with colchicine in community healthcare setting.
Topics: Acetaminophen; Anti-Inflammatory Agents; Azithromycin; Betacoronavirus; Cohort Studies; Colchicine; | 2020 |
Abnormal liver function tests predict transfer to intensive care unit and death in COVID-19.
Topics: Acetaminophen; Antibodies, Monoclonal, Humanized; Antipyretics; Antiviral Agents; COVID-19; Critical | 2020 |
Ibuprofen use and clinical outcomes in COVID-19 patients.
Topics: Acetaminophen; Adult; Antipyretics; COVID-19; COVID-19 Drug Treatment; Female; Fever; Humans; Ibupro | 2020 |
Impact of the COVID-19 pandemic in children with allergic asthma.
Topics: Acetaminophen; Adolescent; Adrenal Cortex Hormones; Adrenergic beta-2 Receptor Agonists; Analgesics, | 2020 |
A COVID-19 patient with intense burning pain.
Topics: Acetaminophen; Analgesics; Asthma-Chronic Obstructive Pulmonary Disease Overlap Syndrome; Back Pain; | 2020 |
Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue.
Topics: Acetaminophen; Angiotensin-Converting Enzyme 2; Animals; Betacoronavirus; Cells, Cultured; Coronavir | 2020 |
Successful orthotopic liver transplantation in a patient with a positive SARS-CoV2 test and acute liver failure secondary to acetaminophen overdose.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; COVID-19; COVID-19 Drug Treatment; Drug Overdose; Fe | 2021 |
Co-codamol okay.
Topics: Acetaminophen; Analgesia; Anti-Inflammatory Agents, Non-Steroidal; Codeine; COVID-19; Dentistry; Dru | 2020 |
Self-medication practice with analgesics (NSAIDs and acetaminophen), and antibiotics among nursing undergraduates in University College Farasan Campus, Jazan University, KSA.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Anti-Inflammatory Agents | 2021 |
Liver transplantation in COVID-19 positive patients.
Topics: Acetaminophen; COVID-19; Humans; Liver Failure, Acute; Liver Transplantation; RNA, Viral; SARS-CoV-2 | 2021 |
Nonsteroidal Antiinflammatory Drugs and Susceptibility to COVID-19.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; | 2021 |
Structural Variability, Expression Profile, and Pharmacogenetic Properties of TMPRSS2 Gene as a Potential Target for COVID-19 Therapy.
Topics: Acetaminophen; Angiotensin-Converting Enzyme 2; Asia; Basigin; COVID-19; COVID-19 Drug Treatment; Cu | 2020 |
Urticaria as a first clinical manifestation of COVID-19.
Topics: Acetaminophen; Adult; Antiviral Agents; Cetirizine; COVID-19; COVID-19 Drug Treatment; Dermatologic | 2020 |
Dual-Mode Gradient HPLC and TLC Densitometry Methods for the Simultaneous Determination of Paracetamol and Methionine in the Presence of Paracetamol Impurities.
Topics: Acetaminophen; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; COVID-19; Densitome | 2021 |
Non-steroidal anti-inflammatory agent use may not be associated with mortality of coronavirus disease 19.
Topics: Acetaminophen; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort St | 2021 |
Exceptional Prices of Medical and Other Supplies during the COVID-19 Pandemic in Ecuador.
Topics: Acetaminophen; Analgesics, Non-Narcotic; COVID-19; COVID-19 Vaccines; Economics, Hospital; Ecuador; | 2021 |
An examination of gastrointestinal absorption using the acetaminophen absorption test in critically ill patients with COVID-19: A retrospective cohort study.
Topics: Acetaminophen; COVID-19; Critical Illness; Humans; Intestinal Absorption; Retrospective Studies; SAR | 2021 |
Paracetamol in the home treatment of early COVID-19 symptoms: A possible foe rather than a friend for elderly patients?
Topics: Acetaminophen; Aged; Antipyretics; COVID-19; COVID-19 Drug Treatment; Glutathione; Home Nursing; Hum | 2021 |
COVID-19'da İhmal Edilen Semptom: Ağrı.
Topics: Acetaminophen; Administration, Oral; Analgesics, Non-Narcotic; Analgesics, Opioid; COVID-19; Humans; | 2021 |
Initial experience of the safety and tolerability of the BNT162b2 (Pfizer-Bio-N-Tech) vaccine in extremely vulnerable children aged 12-15 years.
Topics: Acetaminophen; Adolescent; Adult; Age Factors; BNT162 Vaccine; Child; Comorbidity; COVID-19; Fever; | 2022 |